What should I do if I become resistant to Pralsetinib?

Pralsetinib (Pralsetinib) is a selective RET TKI that has demonstrated clinical activity in patients with RET-altered NSCLC. Preliminary results from plasma ctDNA analysis have identified potential targeted and non-targeted resistance mechanisms in the progression of patients with NSCLC treated with platinib, including meta- and acquired amplification of BRAFV600E. If a patient develops drug resistance after taking platinib, it is recommended to inform the doctor in time.

In some cases, doctors may recommend a combination of treatments, such as targeted drugs combined with traditional chemotherapy, radiation, or immunotherapy. Doctors may also recommend that patients switch to another targeted drug that is effective for your type of cancer. Other options for treatment may exist based on specific genetic mutations or other molecular markers. If you have developed resistance to platinib or other targeted drugs, your doctor may recommend participating in a clinical trial. Clinical trials may provide opportunities for new drugs or treatments that may benefit patients.

It is understood that the original drug Platinib has been launched in China, but it has not yet entered the scope of medical insurance. The price of each box of 100mg*120 tablets may be around 60,000 yuan, which is expensive. The price of the European version of 100mg*60 capsules sold overseas may be around 40,000 yuan per box, and the price of the American version may be around 150,000 yuan per box (prices may fluctuate due to exchange rates). The ingredients of domestic and foreign original drugs are basically the same. There is currently no generic version of Platinib available on the market. Please consult your medical consultant for specific prices and drug details.